HUTCHMED (HCM) Begins Global Phase 1 Trial of KRAS-EGFR Therapy HMPL-A830 in Solid Tumors

HUTCHMED (China) Limited (HCM) announced on September 28, 2026, the initiation of the Phase 1a portion of a global clinical trial evaluating HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors. The trial represents an early-stage study of the KRAS-EGFR targeted therapy, designed to assess safety and tolerability in a difficult-to-treat patient population. Further details regarding enrollment targets, endpoints and study sites were not disclosed in the announcement.